Geron Corporation

432 articles about Geron Corporation

• Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

  3/1/2021

  Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors .

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 18, 2021

  2/18/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 21, 2021

  1/21/2021

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

  1/14/2021

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 19, 2020

  11/19/2020

  Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

• Geron to Present at the Stifel Virtual Healthcare Conference

  11/10/2020

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events . If you are un

• Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events

  11/5/2020

  Geron Corporation, a late-stage clinical biopharmaceutical company, reported financial results for the third quarter ended September 30, 2020.

• Geron Announces Ten Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting

  11/4/2020

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting to be held online from December 5-8, 2020. The abstracts are available on the ASH website a

• Geron to Announce Third Quarter Financial Results on November 5, 2020

  10/29/2020

  Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. A live, listen-only webcast wi

• Geron Announces Publication of IMerge Phase 2 Data in Journal of Clinical Oncology

  10/28/2020

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Journal of Clinical Oncology. The article entitled, “Imetelstat Achieves Meaningful and Durable Transfusion Independence in High-Transfusion Burden Patients with Lower Risk Myelodysplastic Syndr

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 17, 2020

  9/17/2020

  Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

• Geron to Present at the H.C. Wainwright Global Investment Conference

  9/9/2020

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET. A live audio webcast of the presentation will be available on Geron’s w

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 20, 2020

  8/20/2020

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as inducements to four newly-hired employees in connection with commencement of employment with the Company.

• Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events

  8/6/2020

  Geron Corporation, a late-stage clinical biopharmaceutical company, reported financial results for the second quarter ended June 30, 2020.

• Geron to Present at the BTIG Virtual Biotechnology Conference

  8/4/2020

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference

• Geron to Announce Second Quarter Financial Results on August 6, 2020

  7/30/2020

  Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors.

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 16, 2020

  7/16/2020

  Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

• Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes

  7/1/2020

  Designation would provide 10-year period of marketing exclusivity in the European Union after product approval Patients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk myelodysplastic syndromes MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinio

• Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress

  6/12/2020

  For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatment For the IMbark Phase 2 clinical trial, the analyses correlate the potential improvement in overall survival from imetelstat treatment with other clinical benefits observed in the trial, such as fibrosis improvement, as well as symptom and spleen response Data provide further support of ongoing and pla

• Geron Corporation Reports First Quarter 2020 Financial Results

  5/28/2020

  Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020.